Intralesional Metronidazole (5%) VS Intralesional Meglumine Antimonate in Cutaneous Leishmaniasis

Background: Leishmaniasis is a vector-borne disease that causes skin infections around the world through bite of sand fly. This leads to formation cutaneous leishmaniasis and scars on area cosmetically significant. Objective: Our study aimed evaluate efficacy intralesional metronidazole (5%) in comparison with intralesionalmeglumineantimonate treatment leishmaniasis. Methods: In current 40 patients having upto 3 lesions either upper limb, lower
 limb or trunk maximum diameter 3cm longest dimension were included randomly allocated group A (intralesional meglumineantimonate) B metronidazole). Both treatments given as injections weekly basis, for 12 weeks. Patients assessed clinical photographs site taken every visit. The response was recorded according reduction size lesion, flattening change colour, re-epithelialization disappearance signs inflammation. More than 80% improvement complete resolution lesion considered cure. Results: At end weeks 18 out 20 (90%) meglumine antimonite) cured (mean 1.10, SD 0.308), while15 (75%) responded 1.25, 0.444). Although, had better cure rate but both found statistically significant p-value 0.0001. Conclusion: denoted best responds meglumineantimonate butintralesional be safe effective alternative this chronic ailment.